Cancer immunoediting by the innate immune system in the absence of adaptive immunity
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Cancer immunoediting is the process whereby immune cells protect against cancer formation by sculpting the immunogenicity of developing tumors. Although the full process depends on innate and adaptive immunity, it remains unclear whether innate immunity alone is capable of immunoediting. To determine whether the innate immune system can edit tumor cells in the absence of adaptive immunity, we compared the incidence and immunogenicity of 3'methylcholanthrene-induced sarcomas in syngeneic wild-type, RAG2(-/-), and RAG2(-/-)x γc(-/-) mice. We found that innate immune cells could manifest cancer immunoediting activity in the absence of adaptive immunity. This activity required natural killer (NK) cells and interferon γ (IFN-γ), which mediated the induction of M1 macrophages. M1 macrophages could be elicited by administration of CD40 agonists, thereby restoring editing activity in RAG2(-/-)x γc(-/-) mice. Our results suggest that in the absence of adaptive immunity, NK cell production of IFN-γ induces M1 macrophages, which act as important effectors during cancer immunoediting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In line with these findings, microbes may reverse the resistance to immunotherapy through reactivation of IFN-ɤ signaling pathways.”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [91]
Experimental — accuracy not yet measuredIn the citing paper
“IFN-ɤ, an important cytokine involved in antitumor immunity, could upregulate MHC expression on tumor cells and M1 macrophages and facilitate the recognition and elimination of transformed cells (91, 92).”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“…for macrophages that is consistent with studies performed almost 40 yr ago, when it was shown that activated macrophages from infected mice (Hibbs et al., 1971) could kill syngeneic transformed murine embryonic fibroblasts, but not primary nontransformed murine embryonic fibroblasts (Hibbs…”
BackgroundTakahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673 · cited 1×
“Using the 3 methylcholanthrene (MCA) model of sarcomagenesis, we previously found that the immune system in WT mice could edit tumors more effectively than the immune system in RAG2 / mice (which lack adaptive immunity; Shankaran et al., 2001; Takahashi and Yamanaka, 2006), but we did not assess whether tumors from RA…”
MethodCancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Self-citationMonocyte and macrophage heterogeneity
Gordon, S., & Taylor, P. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1733 · Cited by 5,190 · cited 4×
“M1 macrophages are activated classically via IFN- and function in the removal of intracellular pathogens (Gordon and Taylor, 2005).”
BackgroundResultInfluentialThe Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Self-citationThe Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Self-citationIFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896 · cited 13×
“Tumor induction by MCA was performed as previously described (Smyth et al., 2000; Shankaran et al., 2001).”
BackgroundMethodResultInfluentialSelf-citationAlternative Activation of Macrophages: An Immunologic Functional Perspective
Martinez, F. O., Helming, L., & Gordon, S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132532 · Cited by 2,745 · cited 1×
“…characterized by quantitative PCR, using markers known to be associated with an M1-type phenotype (TNF and inducible nitric oxide synthase [iNOS]; Martinez et al., 2009) or with an M2-type phenotype (arginase and epithelial cadherin [eCAD]), growth arrest–specific gene 3 (Gas3; Ghassabeh et al.,…”
MethodDistinct role of macrophages in different tumor microenvironments
Lewis, C. E., & Pollard, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4005 · Cited by 2,225 · cited 2×
“…that these macrophages were classically activated (Gordon and Taylor, 2005) M1 macrophages and performed immunophenotyping to detect the presence of tumor-associated M1 or M2 macrophages, known to have anti- or pro-tumor functions, respectively (Lewis and Pollard, 2006; Sica et al., 2008).”
BackgroundRAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement
Shinkai, Y. (1992) · Cell · doi:10.1016/0092-8674(92)90029-c · Cited by 2,150 · cited 1×
“Genotyping was performed using PCR (for IL-2R c, following The Jackson Laboratories protocol [http://jaxmice.jax.org/strain/003174.html]) or by Southern blot for RAG2 (Shinkai et al., 1992).”
Method
Cited by
Items 201–300 of 348
RETRACTED: Living with Yourself: Innate Lymphoid Cell Immunometabolism
Rolot, M., & O’Sullivan, T. E. (2020) · Cells · doi:10.3390/cells9020334 · Cited by 16
Self-citationRetractedJang, H. J., Caron, C., Lee, C. K., Wang, L., Jama, B., Bui, J. D., & Morris, G. P. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006472 · Cited by 15
Self-citationIslam, M. R., Patel, J., Back, P. I., Shmeeda, H., Kallem, R. R., Shudde, C. E., Markiewski, M. M., Putnam, W. C., Gabizón, A., & La-Beck, N. M. (2023) · Biomolecules · doi:10.3390/biom13091309 · Cited by 15
Kang, J. S., & Dervan, P. B. (2015) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583515000104 · Cited by 16
Checkpoint molecules on infiltrating immune cells in colorectal tumor microenvironment
Talaat, I. M., Elemam, N. M., Zaher, S., & Saber-Ayad, M. M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.955599 · Cited by 17
LncRNA AK089514/miR-125b-5p/TRAF6 axis mediates macrophage polarization in allergic asthma
Zhu, X., He, L., Li, X., Pei, W., Yang, H., Zhong, M., Zhang, M., Lv, K., & Zhang, Y. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02339-1 · Cited by 19
Ottaiano, A., Scala, S., Normanno, N., Napolitano, M., Capozzi, M., Rachiglio, A. M., Roma, C., Trotta, A. M., D’Alterio, C., Portella, L., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6109-z · Cited by 18
Morphometric analysis of immunoselection against hyperploid cancer cells
Bloy, N., Sauvat, A., Chaba, K., Buqué, A., Humeau, J., Pedro, J. M. B., Bui, J. D., Kepp, O., Kroemer, G., & Senovilla, L. (2015) · Oncotarget · doi:10.18632/oncotarget.5400 · Cited by 16
Self-citationMorisada, M. V., Chamberlin, M. M., & Allen, C. T. (2018) · Head & Neck · doi:10.1002/hed.25101 · Cited by 15
Kubick, B. J., Fan, X., Crouch, A., McCarthy, R., & Roop, D. R. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.08.446 · Cited by 17
Marcucci, F., & Rumio, C. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03606-8 · Cited by 15
Johnson, C. L., Green, D. S., & Zoon, K. C. (2014) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2014.0057 · Cited by 14
Enhancing Immune Reconstitution: From Bench to Bedside
van den Brink, M. R. M., Leen, A. M., Baird, K., Merchant, M. S., Mackall, C. L., & Bollard, C. M. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.09.016 · Cited by 15
Role of dendritic cells in the regulation of antitumor immunity
Wathelet, N., & Moser, M. (2013) · OncoImmunology · doi:10.4161/onci.23973 · Cited by 15
So, E. C., Sallin, M. A., Zhang, X., Chan, S. L., Sahni, L., Schulze, D. H., Dávila, E., Strome, S. E., & Jain, A. K. (2013) · Journal of Immunological Methods · doi:10.1016/j.jim.2013.05.001 · Cited by 17
Innate lymphoid cells in early tumor development
Warner, K., Ghaedi, M., Chung, D. C., Jacquelot, N., & Ohashi, P. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.948358 · Cited by 14
Ke, C., Chiu, Y., Huang, K., & Lin, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010147 · Cited by 21
“Therefore, with their high immunogenicity, tumors derived from RAG2−/−x γc−/− mice attract the incremental infiltration of immune cells, followed by tumor remission in WT mice [14].”
BackgroundAnalysis of immune status after iodine-125 permanent brachytherapy in prostate cancer
Du, E., Wang, L., Li, C., Zhang, C., Qu, Y.-C., Liu, R., Xu, Y., Yang, K., & Zhang, Z. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s137491 · Cited by 13
“The ability to suppress cancer by innate and adaptive immunity has been collectively termed cancer immunosurveillance.(11,12) The deficiency in prostate-associated lymphocytes enables a tumor to escape from surveillance on the part of the immune system.”
Spirito, F., Nocini, R., Mori, G., Albanese, M., Georgakopoulou, E. A., Sivaramakrishnan, G., Khalil, B., Špiljak, B., Surya, V., Mishra, D., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312990 · Cited by 16
Velásquez, S. Y., Himmelhan, B. S., Kassner, N., Coulibaly, A., Schulte, J., Brohm, K., & Lindner, H. A. (2020) · Cells · doi:10.3390/cells9030734 · Cited by 14
Understanding the influence of the tumor microenvironment on macrophage responses to CD40 agonists
Luheshi, N., Davies, G., & Legg, J. W. (2014) · OncoImmunology · doi:10.4161/onci.27615 · Cited by 12
Olayiwola, M. O., & Alaje, A. I. (2024) · Healthcare Analytics · doi:10.1016/j.health.2024.100325 · Cited by 11
Chromatin organization as an indicator of glucocorticoid induced natural killer cell dysfunction
Misale, M. S., Janusek, L. W., Tell, D., & Mathews, H. L. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.09.004 · Cited by 13
Rothe, M., Quarcoo, D., Chashchina, A. A., Bozrova, S. V., Qin, Z., Nedospasov, S. A., Blankenstein, T. J. F., Kammertoens, T., & Drutskaya, M. S. (2013) · Cancer Medicine · doi:10.1002/cam4.145 · Cited by 10
Tsukahara, T., Nakamura, S., Romero‐Pérez, G. A., Ohwaki, M., YANAGISAWA, T., & Kan, T. (2018) · Bioscience of Microbiota Food and Health · doi:10.12938/bmfh.17-021 · Cited by 11
TGF-β-mediated suppression of NK cell function and targeting strategies in tumor immunotherapy
Wang, B., & Bi, J. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105141 · Cited by 11
Effects of selenium onPteridium aquilinumand urethane-induced lung carcinogenesis
Nakahara, S. B. R., Sanches, D. S., Caniceiro, B. D., Wysochi, H. L., da Silva, G. B., & Latorre, A. O. (2013) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2013.830125 · Cited by 10
The tricks for fighting against cancer using CAR NK cells: A review
Vahidian, F., Khosroshahi, L. M., Akbarzadeh, M., Jahanban‐Esfahlan, A., Baghbanzadeh, A., Ali‐Hassanzadeh, M., & Safarzadeh, E. (2022) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2022.101817 · Cited by 9
Abnormal Mammary Development in 129:STAT1-Null Mice is Stroma-Dependent
Chen, J. Q., Mori, H., Cardiff, R. D., Trott, J. F., Hovey, R. C., Hubbard, N. E., Engelberg, J. A., Tepper, C. G., Willis, B., Khan, I. H., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129895 · Cited by 11
Self-citationKnockout of immunotherapy prognostic marker genes eliminates the effect of the anti-PD-1 treatment
Yang, N., Ji, F., Cheng, L., Lu, J., Sun, X., Lin, X., & Lan, X. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00175-2 · Cited by 9
Ke, C., Wang, Y., Chiang, H.-C., Wu, H., Liu, W.-J., Huang, C.-C., Huang, Y.-C., & Lin, C. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.11.012 · Cited by 8
Senovilla, L., Galluzzi, L., Castedo, M., & Kroemer, G. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12072 · Cited by 9
Cancer cell-binding peptide fused Fc domain activates immune effector cells and blocks tumor growth
Mobergslien, A., Peng, Q., Vasovič, V., & Sioud, M. (2016) · Oncotarget · doi:10.18632/oncotarget.12445 · Cited by 9
Development and Function of Natural Killer Cells and Its Importance in Cancer Immunotherapy
Paul, S., & Lal, G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809819-6.00009-5 · Cited by 11
MicroRNAs at the Crossroad between Immunoediting and Oncogenic Drivers in Hepatocellular Carcinoma
Gramantieri, L., Fornari, F., Giovannini, C., & Treré, D. (2022) · Biomolecules · doi:10.3390/biom12070930 · Cited by 7
Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?
Bronte, G., Cicero, G., Sortino, G., Pernice, G., Catarella, M. T., D'Alia, P., Cusenza, S., Dico, S. L., Bronte, E., Sprini, D., et al. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.859671 · Cited by 8
Caniceiro, B. D., Latorre, A. O., Fukumasu, H., Sanches, D. S., Haraguchi, M., & Górniak, S. L. (2014) · Journal of Immunotoxicology · doi:10.3109/1547691x.2014.885619 · Cited by 8
Wang, Y., Tan, J., Hu, P., Pei, Q., Wen, Y., Ma, W., Shi, K., Li, Z., Li, H., Cheng, F., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111107 · Cited by 7
Yao, F., Yuan, Q., Yan, Y., Liang, G., Zhou, L., Xu, H., Gao, S., Zou, T., & Zhang, L. (2024) · Scientific Reports · doi:10.1038/s41598-024-83197-7 · Cited by 6
“These cytokines can cause a decrease in the number of immature DCs in the tumor tissue rendering them functionally deficient and unable to stimulate antigen-specific CD8 + T cells, resulting in immune tolerance and placing TIME in an immunosuppressive inflammatory state 34,35 .”
Ezrin, radixin, and moesin are dispensable for macrophage migration and cellular cortex mechanics
Verdys, P., Rey-Barroso, J., Girel, A., Vermeil, J., Bergert, M., Sanchez, T., Métais, A., Mangeat, T., Bellard, E., Bigot, C., et al. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00173-7 · Cited by 11
“C57Bl6Jj female mice were subcutaneous injected 100 μL PBS with 5 × 10 5 MCA Prog (9609) fi brosarcoma tumor cell to induce a fast-growing fi brosarcoma (O ’ Sullivan et al, 2012).”
Pagliuca, S., & Ferraro, F. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.01.002 · Cited by 7
Checkpoint Inhibition for Colorectal Cancer: Progress and Possibilities
Paul, B. A., O’Neil, B. H., & McRee, A. J. (2016) · Immunotherapy · doi:10.2217/imt-2016-0013 · Cited by 6
Identification and editing of stem-like cells in methylcholanthrene-induced sarcomas
Gross, E. T. E., Peinado, C. D., Jung, Y., Han, S., Liu, B., Santosa, E. K., & Bui, J. D. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1404212 · Cited by 6
Self-citationCurrent Concepts in Natural Killer Cell Biology and Application to Drug Safety Assessments
Goyos, A., Fort, M. M., Sharma, A. M., & Lebrec, H. N. (2019) · Toxicological Sciences · doi:10.1093/toxsci/kfz098 · Cited by 6
Yadav, P. K., Gupta, S. K., Kumar, S., Ghosh, M., Yadav, B. S., Kumar, D., Kumar, A., Saini, M., & Kataria, M. (2020) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03908-2 · Cited by 6
Searles, S. C., Chen, W., Yee, J. D., Lee, P., Lee, C. K., Caron, C., Mousovich‐Neto, F., Matei, I. R., Lyden, D. C., & Bui, J. D. (2024) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12515 · Cited by 6
“4862, 6727, d42m1, H31m1, 9609, 9614, d29m1, and F236 MCA sarcoma cell lines were generated previously (O’Sullivan et al., 2012; Shankaran et al., 2001).”
BackgroundMethodInfluentialSelf-citationThe multifaceted role of SMAD4 in immune cell function
Cui, X., Song, Y., Han, J., & Yuan, Z. (2024) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2024.101902 · Cited by 6
Roles of antigen receptors and CA215 in the innate immunity of cancer cells
Lee, G., & Liu, S. (2013) · Open Journal of Immunology · doi:10.4236/oji.2013.33018 · Cited by 7
Effector and cytolytic function of natural killer cells in anticancer immunity
Karmakar, S., Mishra, A., Pal, P., & Lal, G. (2023) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiad126 · Cited by 6
Arthanareeswaran, V., Berndt‐Paetz, M., Ganzer, R., Stolzenburg, J., Ravichandran-Chandra, A., Glasow, A., & Neuhaus, J. (2018) · Laparoscopic Endoscopic and Robotic Surgery · doi:10.1016/j.lers.2018.01.001 · Cited by 5
Coagulation proteases and neurotransmitters in pathogenicity of glioblastoma multiforme
Tripathy, S., Singh, S., Banerjee, M., Modi, D. R., & Prakash, A. (2022) · International Journal of Neuroscience · doi:10.1080/00207454.2022.2107514 · Cited by 6
“Although the previous decade has seen advancements in therapy the recurrence is inevitable and due to these recurring tumours it metastasizes frequently invading the extracellular environment [ 5 ].”
BackgroundReceptors of immune cells mediates recognition for tumors
Anang, V., Singh, A., Kottarath, S. K., & Verma, C. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2022.09.009 · Cited by 5
Peinado, C. D., Kang, X., Hardamon, C. R., Arora, S., Mah, S., Zhang, H., Ngolab, J., & Bui, J. D. (2013) · Immunology · doi:10.1111/imm.12080 · Cited by 5
Self-citationNon-linear tumor-immune interactions arising from spatial metabolic heterogeneityPreprint
Robertson‐Tessi, M., Gillies, R. J., Gatenby, R. A., & Anderson, A. R. A. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/038273 · Cited by 5
Radiation-associated secondary malignancies: a novel opportunity for applying immunotherapies
Atajanova, T., Rahman, M. M., Konieczkowski, D. J., & Morris, Z. S. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03532-1 · Cited by 6
“This results in a tumor cell population with a high level of shared, tumor-specific mutation-associated neoantigens, which are among the most immunogenic tumor antigens recognized by T cells [83, 84].”
BackgroundCXCL12–CXCR4 Axis in Cancer Metastasis
Mir, M. A., Naik, A. Q., Shah, M. Z. U. H., & Zafar, T. (2023) · Springer eBooks · doi:10.1007/978-981-99-4657-0_7 · Cited by 4
Nishime, C., Kawai, K., Yamamoto, T., Katano, I., Monnai, M., Goda, N., Mizushima, T., Suemizu, H., Nakamura, M., Murata, M., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402103 · Cited by 4
NK Cell Proportion and Number Are Influenced by Genetic Loci on Chromosomes 8, 9, and 17
Pelletier, A., Guilbault, L., Guimont‐Desrochers, F., Hillhouse, E. E., & Lesage, S. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502284 · Cited by 4
Zhou, H., Yuan, Y., & Qian, H. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10170 · Cited by 5
Cancer Immunosurveillance by Natural Killer Cells and Other Innate Lymphoid Cells
Guillerey, C., & Smyth, M. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_9 · Cited by 5
Self-citationCD47 is associated with the up-regulation of the PD-1 oncogenic signaling pathway.
Yao, D., Xia, J., Li, J., & Xu, J. (2018) · Europe PMC (PubMed Central) · Cited by 4
Immunoediting is not a primary transformation event in a murine model of MLL-ENL AML
Dudenhöffer‐Pfeifer, M., & Bryder, D. (2018) · Life Science Alliance · doi:10.26508/lsa.201800079 · Cited by 3
Verdys, P., Rey-Barroso, J., Vermeil, J., Bergert, M., Sanchez, T., Métais, A., Mangeat, T., Bellard, E., Bigot, C., Girard, J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.27.550674 · Cited by 4
Innate immunity in tumour immunoediting and immunosurveillance
Zhang, Z., Zhang, Y., & Lieberman, J. (2025) · The EMBO Journal · doi:10.1038/s44318-025-00650-7 · Cited by 8
“…without adaptive immunity, was established in a study more than ten years ago by comparing spontaneously arising sarcomas induced by methylcholanthrene in wild-type mice, adaptive immune-de fi cient Rag2 − / − mice and Rag2 − / − γ c − / − mice, which lack all lymphocytes (O ’ Sullivan et al, 2012).”
Okecha, T., Yahaya, J. J., Waiswa, A., Nyakato, V., Anatoli, M., Bogere, N., Lutada, L. A., & Niyonzima, N. (2025) · Breast Cancer Basic and Clinical Research · doi:10.1177/11782234251392693 · Cited by 3
Shallal, A. F., Razaq, C. H., & Owaid, M. N. (2025) · Journal of Macrofungi · doi:10.65999/macrofungi.2025.27 · Cited by 6
Novel technologies for applying immune checkpoint blockers
Awad, R. M., & Breckpot, K. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2023.03.003 · Cited by 3
Natural Killer Cell–Mediated Cytotoxicity Shapes the Clonal Evolution of B-cell Leukemia
Buri, M. C., Shoeb, M. R., Bykov, A., Repiščák, P., Baik, H., Dupanovic, A., David, F. O., Kovačic, B., Hall‐Glenn, F., Dopa, S., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0189 · Cited by 4
“In the context of cancer immunoediting, NK cells play a crucial role in eliminating tumour cells (8) and limiting their metastatic spread (9).”
Cancer Nanomedicine: Special Focus on Cancer Immunotherapy
Tavakolpour, S., & Karami, F. (2020) · Springer eBooks · doi:10.1007/978-3-030-50287-4_26 · Cited by 3
Li, Y., Li, J., Gong, Z., Pan, X.-H., Ma, Z., Ma, S., Wang, H., Dong, H., Gong, F., & Gao, X. (2019) · Molecules · doi:10.3390/molecules24203640 · Cited by 3
Rotte, A., & Bhandaru, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-48066-4_16 · Cited by 3
Immunoediting in SARS-CoV-2: Mutual relationship between the virus and the host
Kheshtchin, N., Bakhshi, P., Arab, S., & Nourizadeh, M. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108531 · Cited by 2
Saad, H., Baz, A., Riad, M., Eraky, M. E., El-Taher, A. K., Farid, M. I., Sharaf, K., Said, H. E. M., & Ibrahim, L. A. (2024) · BMC Immunology · doi:10.1186/s12865-023-00591-y · Cited by 3
“Innate immunity, an alternative immune-based therapy, is also being explored, with novel therapies such as anti-CSF1R blocking TAMs’ receptors that recruit and activate M2 pro-tumor immune cells [27–33”
BackgroundRetractedPrognostic impact of circulating monocyte subsets in pediatric solid tumors
Zahran, A. M., Rayan, A., Sayed, H. A. R., Sobhy, A., Solimn, A., & Darwish, A. M. (2019) · Cancer Biomarkers · doi:10.3233/cbm-182212 · Cited by 2
“…microenvironment, in addition, PFS and OS were significantly worse in patients with high level of TAMs and concluded that the level of peripheral blood monocytes was a useful negative prognostic marker [25], our results were contradictory to these results as NCM was correlated positively with OS.”
Bald, T., & Smyth, M. J. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.09.015 · Cited by 2
Self-citationCzerwińska, U. (2018) · theses.fr (ABES) · doi:10.70675/ba480b3dze0c8z442dz9b9czc363d3107e66 · Cited by 4
The Cancer Research Institute 2013 Annual Symposium: Dynamics of Host–Tumor Interaction
Tontonoz, M. J., & Gee, C. E. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0225 · Cited by 2
Alshammary, A. F., Al-Toub, M., Albukhari, T. A., & Filimban, W. A. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815124606123010009 · Cited by 1
Zhang, W., Zeng, S., Dou, J., & Yu, C. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1608222 · Cited by 2
Kuwahara, A. A., Fenton, E. M., Lovejoy, C., Lee, T., Wang, L., Fogarty, M. M., Jung, J., Guo, S.-M., Maynard, L. H., May, A. P., et al. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201183 · Cited by 1
THE ROLE OF THE IL-17/IL-17R AXIS IN BREAST TUMOR GROWTH AND METASTASIS
Dawod, B. (2016) · DalSpace (Dalhousie University) · Cited by 1
Bisson, W. H., Amedei, A., Memeo, L., Forte, S., & Felsher, D. W. (2017) · John Wiley & Sons, Inc. eBooks · doi:10.1002/9781119023647.ch14 · Cited by 2
Immunology of Cytokine Storm Syndromes: Natural Killer Cells
French, A. R., & Cooper, M. A. (2019) · Springer eBooks · doi:10.1007/978-3-030-22094-5_10 · Cited by 1
Ke, C., Wu, H., Wang, Y., Huang, W., & Lin, C. (2024) · Biomedicines · doi:10.3390/biomedicines12040846 · Cited by 1
“Tumor-free mice were defined as having a tumor mass below 9 mm in average diameter at day 14 [20].”
BackgroundEgbulefu, C., Black, K. C. L., Su, X., Partha, K., Habimana-Griffin, L., Sudlow, G. P., Prior, J. L., Onejeme, E., Zheleznyak, A., Xu, B. J., et al. (2026) · Communications Biology · doi:10.1038/s42003-026-09555-5 · Cited by 2
Self-citationUnchaining NK cell–mediated anticancer immunosurveillance
Zitvogel, L., & Kroemer, G. (2016) · Nature Immunology · doi:10.1038/ni.3471 · Cited by 1
Unexpected link between insect innexins and apoptosis of HeLa cells
Zhang, W., Liu, M., Li, M., Xiao, W., Zhang, X., He, H., Chen, Y., Ding, L., & Luo, K. (2018) · Archives of Insect Biochemistry and Physiology · doi:10.1002/arch.21473 · Cited by 1
Improving responses to immunotherapy in head and neck squamous cell carcinoma
Ye, W., Schmitt, N. C., Ferris, R. L., & Allen, C. T. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817868-3.00006-8 · Cited by 2
Efremova, M., Klepsch, V., Charoentong, P., Finotello, F., Rieder, D., Hackl, H., Hermann‐Kleiter, N., Löwer, M., Baier, G., Krogsdam, A., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/099747 · Cited by 1
Studies on IL-15 mediated anti-tumour immune responses in prostate cancer
Sakellariou, C. A. (2017) · Research Portal (King's College London) · Cited by 1
Immunomodulation and Genomic Instability
Reid, G. S. D. (2014) · Cancer metastasis · doi:10.1007/978-3-319-12136-9_8
Combined chemotherapy and immunotherapy against experimental malignant brain tumors
Fritzell, S. (2013) · Lund University Publications (Lund University)
Inflammation, Tumor Progression, and Immune Suppression
Ostrand‐Rosenberg, S., & Sinha, P. (2013) · Springer eBooks · doi:10.1007/978-94-007-6217-6_7
Modelling of tumour-induced angiogenesis with regress by immune factor
Chen, W., Li, Z., Shao, L., Bass, R., Liu, C., & Hossain, A. (2015) · International Conference on Software, Knowledge, Information Management and Applications (SKIMA) · doi:10.1109/skima.2015.7399991
VISUALIZING THE DYNAMICS OF IMMUNE SURVEILLANCE IN BRAIN TUMORS BY INTRAVITAL MULTIPHOTON MICROSCOPY
Nwajei, F. (2017) · Digital Commons-TMC (Texas Medical Center)
Furuzawa, K. M. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2017.tde-18012017-145414
Modelling of Tumour-induced Angiogenesis
Chen, W. (2015) · Northumbria Research Link (Northumbria University)
Medrano, R. F. V. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2018.tde-06042018-122815
Metadata
- Authors
- O’Sullivan, T., Saddawi-Konefka, R., Vermi, W., Koebel, C. M., Arthur, C., White, J. M., Uppaluri, R., Andrews, D. M., Ngiow, S. F., Teng, M. W. L., Smyth, M. J., Schreiber, R. D., & Bui, J. D.
- Affiliations
- University of California San Diego (US)
- Department of Pathology, University of California at San Diego, La Jolla, CA 92093 1
- University of Brescia (IT)
- Washington University in St. Louis (US)
- Center for Immunology, Department of Pathology and Immunology 3 and 4
- The University of Melbourne (AU)
- Corresponding author
- Bui, Jack D.
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2012-08-27
- Volume
- 209
- Issue
- 10
- Pages
- 1869-1882
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC3457735
- OpenAlex
- W2144577255
- Cited by
- 348
- References
- 58
- Citations by year
- 2026: 11 · 2025: 8 · 2024: 24 · 2023: 31 · 2022: 22 · 2021: 30 · 2020: 29 · 2019: 25 · 2018: 32 · 2017: 30 · 2016: 27 · 2015: 23 · 2014: 21 · 2013: 29 · 2012: 6
- FWCI
- 11.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-sa)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion, public-domain)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-sa)
- Funders
- Cancer Research Institute
- Concern Foundation
- Hartwell Foundation (CA157885)
- Ludwig Institute for Cancer Research
- Cancer Research Coordinating Committee
- National Institutes of Health (CA157885)
- Medical Research Council
- National Health and Medical Research Council
- National Cancer Institute (CA 107527, CA128893, K08CA128893, K08CA090403, R01CA043059, R01CA157885, CA-43059, R37CA043059, R01CA107527, CA157885)
- National Center for Research Resources (C06RR012466)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- cancer immunoediting, innate immunity, natural killer cells, interferon-gamma, M1 macrophages, CD40 agonist, Rag2 knockout mice, tumor immunogenicity, adaptive immunity
- MeSH terms
- Animals, Histocompatibility Antigens Class II, DNA-Binding Proteins, Immunity, Innate, Interferon-gamma, Killer Cells, Natural, Macrophages, Neoplasms, Phenotype, Sarcoma, Transplantation, Isogeneic, Mice, Knockout, CD40 Antigens, Genetic Predisposition to Disease, Cell Line, Tumor, Mice, Interleukin Receptor Common gamma Subunit, Adaptive Immunity, Immunomodulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.